Biotech Firm Sees Stock Supply Trade 20 Times In Single Day Ahead Of Stock Exchange Deadline

2026-08-19 companies

New York, Wednesday, 19 August 2026.
Biomedical company OSR Health experienced unprecedented trading volume, exchanging its entire public stock supply twenty times in one day as leadership prepares to challenge a potential exchange removal.

Unprecedented Trading Volume and Market Volatility

On Monday, August 17, 2026, biomedical technology firm OSR Health (NASDAQ: OSRH) experienced an extraordinary surge in market interest, trading 370 million shares and ranking as the number-one most active stock on the Nasdaq exchange [1]. This massive trading volume represents an extreme turnover rate compared to the company’s public float of approximately 18.5 million shares, meaning the entire public float was traded more than 20 times in a single day [1]. Driven by this intense momentum, OSRH shares surged by 93.04% to close at $0.61 during the Monday session [4], recovering from a 32.36% decline over the 30-day period preceding the spike [4].

The Battle for Nasdaq Listing Compliance

This extreme trading volatility occurs at a critical juncture for OSR Health as it navigates listing challenges. The company’s compliance difficulties began on September 5, 2025, when it was notified that its stock had traded below the Nasdaq minimum bid price of $1.00 for 30 consecutive business days [3]. Although OSR Health received a 180-day extension to regain compliance [2], it faces an upcoming regulatory deadline of August 31, 2026, to restore its share price above the $1.00 threshold [2]. As of today, August 19, 2026, the company has not received any official communication from the Nasdaq Listing Qualification Department regarding its compliance status [1].

Strategic Milestones and Shifting Institutional Positions

The speculative interest in OSR Health is also tied to its ongoing oncology asset developments. In April 2026, the company and Vaximm signed a global exclusive license agreement for VXM01 with BCM Europe, which includes potential milestone payments of up to $815 million and an equity purchase provision of up to $15 million of OSRH common stock at $10.00 per share [2]. OSR Health subsequently acquired the full VXM01 intellectual property portfolio for $30 million in May 2026 to consolidate its royalty and milestone economics [2]. Additionally, leadership has committed to continuing its Shareholder Loyalty Contingent Value Rights (CVR) program regardless of its final exchange listing status, and is currently preparing an S-1 registration statement [1].

Sources

Nasdaq Compliance OSR Health